Fine Foods & Pharmaceuticals N.T.M. (BIT: FF) revenue
Fine Foods & Pharmaceuticals N.T.M. reported revenue of €253.5m for fiscal 2025, 3.4% more than in fiscal 2024 (€245.1m). Since fiscal 2021 its revenue has grown by 29.8%, an average growth of 6.7% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | €253.5m | +3.4% | €16.4m | 6.5% |
| 2024 | €245.1m | −3.1% | €14.6m | 6.0% |
| 2023 | €252.9m | +21.4% | €1.1m | 0.4% |
| 2022 | €208.3m | +6.7% | −€1.0m | −0.5% |
| 2021 | €195.2m | — | €5.0m | 2.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the revenue of Fine Foods & Pharmaceuticals N.T.M.
- How much revenue did Fine Foods & Pharmaceuticals N.T.M. make in fiscal 2025?
- Fine Foods & Pharmaceuticals N.T.M. reported revenue of €253.5m for fiscal 2025, compared with €245.1m in fiscal 2024.
- How much has the revenue of Fine Foods & Pharmaceuticals N.T.M. grown?
- Between fiscal 2021 and fiscal 2025 it went from €195.2m to €253.5m: 29.8% more, an average growth of 6.7% a year.
- What was the best year for revenue at Fine Foods & Pharmaceuticals N.T.M.?
- Of its last 5 fiscal years, fiscal 2025, with €253.5m.
- Where do the figures for Fine Foods & Pharmaceuticals N.T.M. come from?
- From the report Fine Foods & Pharmaceuticals N.T.M. files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Fine Foods & Pharmaceuticals N.T.M. files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Fine Foods & Pharmaceuticals N.T.M.: the Fine Foods & Pharmaceuticals N.T.M. page · annual accounts · net income · dividends paid.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.